Market Cap 655.32M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 14.08
Forward PE 9.63
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 411,400
Avg Vol 1,147,316
Day's Range N/A - N/A
Shares Out 30.47M
Stochastic %K 82%
Beta 0.89
Analysts Strong Sell
Price Target $23.38

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 314 6297
Address:
1050 Waltham Street, Suite 302, Lexington, United States
sprmn
sprmn Dec. 10 at 11:37 PM
$KROS 🚀🚀🚀💪
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 1:11 AM
$KROS Share Price: $21.52 Contract Selected: Jun 18, 2026 $22.5 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.71 – $5.76 Potential Upside: 75% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
sprmn
sprmn Dec. 8 at 2:26 PM
1 · Reply
sprmn
sprmn Dec. 8 at 2:23 PM
$KROS Release the KRAKEN! Takeda….
0 · Reply
Uncle_Tom
Uncle_Tom Dec. 7 at 10:06 AM
$KROS not selling before gapclose
1 · Reply
Investor6
Investor6 Dec. 7 at 9:40 AM
$GTEC Current financial condition according to the 9 months results: Market Cap: $18.5 million Revenues (9-month): $66.8 million Gross Profit (9-month): $46.8 million Net Income (9-month): $8.4 million EPS (9-month): $0.41. All metrics would be much improved without the one-time expenses of Q2. The Enterprise Value is still Negative, by buying a share you own more cash minus liabilities than what you pay. For 2025: With EPS of Q3 at $0.33, the 2025 EPS could be at the range of $0.68 to $0.81 (Q4 EPS: from $0.25 to $0.40). The 2025 Revenues range could be from $84 million to $90 million. These numbers shape a P/E below 2 and a Market Cap to Sales below 0.25. Metrics like EV/Sales, EV/EBITDA are negative. For example, with GTEC stock at $2.00, EV/EBITDA is still below 1.5! With these numbers, GTEC is in the top-5 of undervalued stocks by almost any metric. In EV/EBITDA is ranked in No1 among $KROS $CISS $IMPP and $MYPS
2 · Reply
CoinRaider
CoinRaider Dec. 6 at 10:01 PM
$KROS Up 24% in a week shortly after green mail buyback completed. Something strange cooking.
0 · Reply
sprmn
sprmn Dec. 6 at 1:32 AM
$KROS Remember GME squeeze? Now, it’s KROS turn.
0 · Reply
okiejames
okiejames Dec. 5 at 8:39 PM
$KROS been selling cover calls for about a year now. I finally decided time to stop since its been making these moves.
0 · Reply
Doozio
Doozio Dec. 5 at 8:37 PM
ARE yo walking $ENTA da weekend wit da $KROS who ain’t yo BROS GRABing dese $NUTX $SYM thing about 🐒🍌🧠⏰♾️
0 · Reply
Latest News on KROS
Keros Therapeutics Announces Final Results of Tender Offer

Nov 20, 2025, 4:01 PM EST - 24 days ago

Keros Therapeutics Announces Final Results of Tender Offer


Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 7 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value


Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 8 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump


Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 8 months ago

Keros Therapeutics adopts 'poison pill' plan


Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 8 months ago

Keros Therapeutics Announces Review of Strategic Alternatives


sprmn
sprmn Dec. 10 at 11:37 PM
$KROS 🚀🚀🚀💪
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 1:11 AM
$KROS Share Price: $21.52 Contract Selected: Jun 18, 2026 $22.5 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.71 – $5.76 Potential Upside: 75% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
sprmn
sprmn Dec. 8 at 2:26 PM
1 · Reply
sprmn
sprmn Dec. 8 at 2:23 PM
$KROS Release the KRAKEN! Takeda….
0 · Reply
Uncle_Tom
Uncle_Tom Dec. 7 at 10:06 AM
$KROS not selling before gapclose
1 · Reply
Investor6
Investor6 Dec. 7 at 9:40 AM
$GTEC Current financial condition according to the 9 months results: Market Cap: $18.5 million Revenues (9-month): $66.8 million Gross Profit (9-month): $46.8 million Net Income (9-month): $8.4 million EPS (9-month): $0.41. All metrics would be much improved without the one-time expenses of Q2. The Enterprise Value is still Negative, by buying a share you own more cash minus liabilities than what you pay. For 2025: With EPS of Q3 at $0.33, the 2025 EPS could be at the range of $0.68 to $0.81 (Q4 EPS: from $0.25 to $0.40). The 2025 Revenues range could be from $84 million to $90 million. These numbers shape a P/E below 2 and a Market Cap to Sales below 0.25. Metrics like EV/Sales, EV/EBITDA are negative. For example, with GTEC stock at $2.00, EV/EBITDA is still below 1.5! With these numbers, GTEC is in the top-5 of undervalued stocks by almost any metric. In EV/EBITDA is ranked in No1 among $KROS $CISS $IMPP and $MYPS
2 · Reply
CoinRaider
CoinRaider Dec. 6 at 10:01 PM
$KROS Up 24% in a week shortly after green mail buyback completed. Something strange cooking.
0 · Reply
sprmn
sprmn Dec. 6 at 1:32 AM
$KROS Remember GME squeeze? Now, it’s KROS turn.
0 · Reply
okiejames
okiejames Dec. 5 at 8:39 PM
$KROS been selling cover calls for about a year now. I finally decided time to stop since its been making these moves.
0 · Reply
Doozio
Doozio Dec. 5 at 8:37 PM
ARE yo walking $ENTA da weekend wit da $KROS who ain’t yo BROS GRABing dese $NUTX $SYM thing about 🐒🍌🧠⏰♾️
0 · Reply
okiejames
okiejames Dec. 5 at 8:37 PM
0 · Reply
Investknowledge
Investknowledge Dec. 5 at 3:41 PM
0 · Reply
sprmn
sprmn Dec. 5 at 3:11 PM
$KROS wah really 🚀🚀🚀
0 · Reply
sprmn
sprmn Dec. 4 at 8:13 PM
$KROS short squeezed
0 · Reply
CoinRaider
CoinRaider Dec. 4 at 8:08 PM
0 · Reply
sprmn
sprmn Dec. 4 at 7:55 PM
$KROS 42% short…
0 · Reply
Doozio
Doozio Dec. 4 at 6:03 PM
$KROS 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Dec. 4 at 6:01 PM
If da $KROS are da pros then let’s walk into ENTA da weekend…….
0 · Reply
Doozio
Doozio Dec. 4 at 4:30 PM
$KROS chop chop huckleberries…. It was always 🐒🍌🧠⏰♾️
0 · Reply
CyberCuba
CyberCuba Dec. 3 at 6:21 PM
$KROS 210 KROS December $20 call options purchased already today. Never seen so many calls purchased like this for KROS. Someone may know something since Goldman Sachs has been retained over the last few months by KROS to increase shareholder value.
1 · Reply
CyberCuba
CyberCuba Dec. 3 at 6:19 PM
$KROS 210 December $20 call options already purchased today. Someone may know something!
0 · Reply
CyberCuba
CyberCuba Nov. 29 at 6:07 PM
$KROS Only 11 million of the 16 million tendered shares were purchased by the company leaving 5 million wannabe shares to be sold. I suspect it will take 10 to 14 trading days to clear out the excess as people totally liquidate in the $17 to $17.50 range. If so, around December 8, we should continue slowly upward. $20 per share by Christmas is doable if not earlier.
0 · Reply